Detail akcie Cassava Sci Rg online

Business Summary: Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cassava Sciences Inc revenues was not reported. Net loss increased 28% to $97.2M. Higher net loss reflects Other General & Admin increase of 21% to $14M (expense), Stock-Based Compensation Expense increase from $435K to $2.5M (expense), Other income, net decrease of 9% to $907K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.90 to -$2.32.